D. Farrukh

3 та иш

Tashkent Medical Park Llc, HOD Oncology Department, Tashkant, Uzbekistan

1. 75eP Mutational spectrum of KRAS, TP53, BRAF, ERBB2, and POLE in GI malignancies across diverse populations

   Nikhil Ghadyalpatil, Umut Dişel, O. Zilola +15

   МақолаChromatin Remodeling and CancerESMO Open20250 иқтибос

   ABIABI:AkademIndex/openalex/2025.article.008761

2. Abstract 2510: Comprehensive genomic profiling drives precision oncology and expands accessibility to targeted therapies in Uzbek populations

   Zilola Avazovna Olimova, Gowhar Shafi, D. Farrukh +10

   МақолаCancer Genomics and DiagnosticsCancer Research20260 иқтибос

   ABIABI:AkademIndex/openalex/2026.article.010172

3. Abstract 3141: Integrative genomic analysis reveals pharmacogenomic determinants of chemotherapy response

   D. Farrukh, Yashodhara Bhattacharya, Mohan Uttarwar +8

   МақолаPharmacogenetics and Drug MetabolismCancer Research20260 иқтибос

   ABIABI:AkademIndex/openalex/2026.article.010238